Jump to content
The World News Media

BioMarin Withdraws European Application for Kyndrisa - Genetic Engineering & Biotechnology News


Health and Medicine

Recommended Posts

  • Administrator
images?q=tbn:ANd9GcTyL8v5wI9j0Cn45YsbZOh
Tech Times

BioMarin Withdraws European Application for Kyndrisa
Genetic Engineering & Biotechnology News
BioMarin Pharmaceutical said today it has withdrawn its Marketing Authorization Application (MAA) for Kyndrisa™ (drisapersen), the company's drug candidate for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. BioMarin said it will also ...
BioMarin Withdraws Kyndrisa Marketing Application in EUZacks.com
Business News Roundup, June 1SFGate
BioMarin To Halt Development Of $680M Duchenne Muscular Dystrophy DrugTech Times

all 24 news articles »

Google

Link to comment
Share on other sites


  • Views 286
  • Replies 0
  • Created
  • Last Reply

Top Posters In This Topic

Popular Days

Top Posters In This Topic

Popular Days

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...




×
×
  • Create New...

Important Information

Terms of Service Confirmation Terms of Use Privacy Policy Guidelines We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.